Selenium for Immune Function

Selenium's role in immune defense became unforgettable in 1995, when Melinda Beck and Orville Levander demonstrated something nobody had previously imagined possible — that nutritional deficiency in the host can drive a benign virus to mutate into a virulent one. Passaging a mild strain of Coxsackievirus B3 through selenium-deficient mice produced six specific point mutations in the viral genome that converted the virus into the cardiotoxic form responsible for Keshan disease, an endemic cardiomyopathy that had been killing children in selenium-poor regions of China for decades. Once it became virulent in the deficient host, the mutated virus retained its cardiotoxicity even when transmitted to selenium-replete mice. Selenium deficiency, in other words, was not just compromising the host's defense — it was actively selecting for more dangerous pathogens. This deep dive walks through that Keshan / Coxsackie story, the consequences for T-cell proliferation and macrophage function, the selenium-HIV CD4 relationship, the influenza-severity data, sepsis-IV selenium trials, and the unexpectedly important SELECT-trial high-grade-prostate-cancer signal that has reframed how clinicians think about supplementing selenium-replete adults.

The Keshan / Coxsackievirus B3 Story
Viral Mutation Prevention as an Immune Function
T-Cell Proliferation and Differentiation
Macrophage and NK-Cell Function
Selenium and HIV / CD4 Counts
Selenium and Influenza Severity
Sepsis IV Selenium Trials
The SELECT Trial Prostate-Cancer Signal
Adult Clinical Applications
Cautions and the Replete-Patient Problem
Key Research Papers
Connections

The Keshan / Coxsackievirus B3 Story

Keshan disease is an endemic dilated cardiomyopathy first described in 1935 in Keshan County, Heilongjiang Province in northeastern China. The disease appeared in spatially clustered seasonal outbreaks, predominantly affecting children and women of childbearing age, with mortality from acute or subacute heart failure reaching 30 to 50 percent of cases in the worst-affected villages. Chinese epidemiologists determined by the late 1970s that the disease occurred almost exclusively in a belt of selenium-deficient soil stretching from northeastern China through Tibet, and that prophylactic selenium supplementation (initially as sodium selenite tablets distributed by village health workers) dramatically reduced incidence. By the mid-1980s, mass selenium supplementation had largely eliminated new cases.

But selenium supplementation alone did not explain everything. Keshan disease had a striking seasonal and geographic clustering that pure nutritional deficiency could not account for — outbreaks occurred in waves that respected village boundaries and seasonal patterns more consistent with an infectious agent than a nutritional disease. The pieces came together in the 1990s, when Melinda Beck, Orville Levander, and colleagues published a remarkable series of experiments at the USDA and the University of North Carolina.

Beck and Levander infected selenium-deficient mice and selenium-replete mice with a mild, non-cardiotoxic strain of Coxsackievirus B3 (CVB3/0). The selenium-replete mice cleared the virus without cardiac damage. The selenium-deficient mice developed myocarditis and inflammatory cardiac lesions identical to Keshan-disease histology.
When they then passaged virus recovered from the selenium-deficient mice through fresh selenium-replete mice, the recipient mice also developed myocarditis — the virus had now acquired cardiotoxicity that persisted regardless of host selenium status.
Sequencing the recovered virus revealed six specific point mutations in the CVB3 genome (changes at nucleotides 234, 788, 2271, 2438, 3324, and 7334) that were stably present in the now-virulent strain and absent from the original mild parental strain.
The same passage-through-deficient-host pattern produced virulent variants from a mild strain of influenza A as well, suggesting the selection mechanism was not Coxsackievirus-specific.

This was a paradigm shift in microbiology and nutrition. The conventional understanding of nutritional immunology had been that micronutrient deficiency weakens the host's ability to fight an unchanging pathogen. Beck and Levander showed that micronutrient deficiency can also drive directional pathogen evolution — the deficient host is not just easier to infect, it is an incubator for the appearance of more virulent strains. The proposed mechanism: the increased oxidative stress in selenium-deficient host cells accelerates the mutation rate of RNA viruses (which already have error-prone polymerases), and the resulting mutational pressure preferentially selects for variants with enhanced replication or tissue tropism.

Back to Table of Contents

Viral Mutation Prevention as an Immune Function

The Beck-Levander findings have been replicated for several other RNA viruses and have implications well beyond Keshan disease.

Influenza A – Subsequent work showed selenium-deficient mice infected with mild influenza A/Bangkok/1/79 strain produced virus with 29 stable point mutations not found in the parental strain, including mutations in the hemagglutinin (HA) and matrix (M) genes known to affect virulence and tropism.
HIV – In vitro work in HIV-infected cell cultures shows that selenium supplementation (in the form of sodium selenite) suppresses HIV replication and reduces the rate of accumulation of HIV genome mutations, suggesting a similar mechanism may operate for retroviruses.
Hepatitis C – Observational studies of hepatitis C virus patients in selenium-poor regions show higher rates of viral quasispecies diversity (a marker of mutation rate) than in selenium-replete populations.
Hantavirus and other RNA virus zoonoses – Several emerging zoonotic outbreaks have been epidemiologically linked to selenium-deficient regions, and this is one of the proposed contributing factors.

The mechanistic explanation is that RNA viruses have intrinsically high error rates because their RNA-dependent RNA polymerases lack proofreading activity. The error rate per replication cycle is the multiplicative product of polymerase fidelity and the oxidative-stress level of the host cell. Selenium-dependent GPx and TrxR enzymes reduce host-cell oxidative stress, lowering the spontaneous mutation rate of the replicating viral genome. Under selenium deficiency, the elevated oxidative stress acts as a mutagen on viral RNA, and the natural-selection bottleneck that follows favors variants with enhanced fitness in the deficient-host environment — which often correlates with virulence.

Back to Table of Contents

T-Cell Proliferation and Differentiation

Beyond the unusual host-pathogen-mutation effect, selenium plays a more conventional role in adaptive immunity at the level of T-cell biology.

T-cell receptor (TCR) signaling – TCR engagement triggers a signaling cascade that includes oxidation of the protein tyrosine phosphatase SHP-2, which acts as a redox-sensitive brake on downstream signaling. Selenoenzyme activity calibrates this redox brake; selenium-deficient T cells show abnormal TCR signaling and impaired clonal expansion.
Clonal proliferation – The thioredoxin-reductase / ribonucleotide-reductase pathway described on the Antioxidant Defense page is rate-limiting for the deoxyribonucleotide pool needed to support the rapid DNA replication of clonally expanding T cells. Selenium-deficient T cells proliferate more slowly in response to antigen stimulation.
Th1 / Th2 / Th17 / Treg balance – Selenium supplementation in human trials has shifted the cytokine profile toward Th1 dominance (IFN-gamma, IL-2) with modest reduction in Th2 cytokines. There is less Th17/Treg literature for selenium than there is for vitamin D or retinoic acid, but observational data suggest similar redox-dependent effects.
Memory T-cell generation – The differentiation of effector T cells into long-lived memory T cells is metabolically demanding and depends on oxidative phosphorylation, mitochondrial biogenesis, and tight redox regulation — all processes dependent on selenoprotein-mediated antioxidant defense, particularly mitochondrial TrxR2.
Antibody responses – Selenium-supplemented adults given seasonal influenza vaccine in several small trials showed modest improvements in seroconversion rates and antibody titers, particularly in elderly populations with marginal baseline selenium status.

Back to Table of Contents

Macrophage and NK-Cell Function

The innate immune system depends on selenium-containing enzymes for both effector function and self-protection.

Macrophage respiratory burst – Activated macrophages and neutrophils generate massive amounts of superoxide and hydrogen peroxide via NADPH oxidase to kill engulfed pathogens. Without adequate GPx activity to confine that oxidative attack to the phagolysosome, the cell damages itself. Selenium-deficient macrophages show impaired phagocytic killing of intracellular bacteria (Listeria, Salmonella, Mycobacterium tuberculosis) and shorter functional lifespan.
M1 / M2 polarization – Selenium promotes the M1 (classically activated, pro-inflammatory, anti-tumor) phenotype over the M2 (alternatively activated, tissue-repair, tumor-promoting) phenotype. This is part of the rationale for selenium's anti-tumor effects on the Cancer Prevention page.
Natural killer (NK) cell cytotoxicity – Multiple clinical studies have documented that selenium supplementation (typically 200 mcg/day for 8 to 16 weeks) increases NK cell cytotoxic activity in selenium-marginal subjects. The mechanism involves both improved redox protection of NK cells during cytotoxic effector function and enhanced expression of NK-activating receptors.
Neutrophil function – Selenium-deficient neutrophils show reduced superoxide generation, impaired chemotaxis, and reduced lifespan. In humans receiving total parenteral nutrition without selenium, neutropenia and impaired neutrophil function have been documented and reverse with selenium repletion.
Dendritic cell maturation – Less well-characterized than the T-cell and macrophage effects, but selenium-deficient dendritic cells show impaired antigen-presenting function and reduced expression of co-stimulatory molecules CD80 and CD86.

Back to Table of Contents

Selenium and HIV / CD4 Counts

HIV infection is associated with progressive depletion of plasma selenium, which falls in proportion to CD4 count and serves as an independent predictor of mortality in untreated HIV patients. The relationship is so robust that low plasma selenium was incorporated into pre-ART-era HIV staging tools as a mortality risk marker.

Baker et al. 1997 – Established that low serum selenium (<85 ng/mL) was associated with a roughly 10-fold increase in mortality in HIV-infected patients independent of CD4 count, opportunistic infection history, and antiretroviral use.
Hurwitz et al. 2007 (Miami HIV trial) – 174 HIV-positive adults randomized to 200 mcg/day selenomethionine vs placebo for 9 months. Selenium supplementation produced significant suppression of HIV viral load progression (mean increase of 0.5 log copies/mL in placebo vs 0.04 log in selenium arm) and significant preservation of CD4 cell counts. The effect was strongest in subjects with the lowest baseline selenium.
Kupka et al. 2008 (Tanzania pregnancy trial) – Selenium supplementation in HIV-positive pregnant women in selenium-deficient Tanzania reduced the rate of acute diarrhea but did not affect mother-to-child HIV transmission rates.
ART-era updates – In patients on effective antiretroviral therapy with suppressed viral loads, the selenium-CD4 relationship is much weaker, and selenium supplementation in well-managed ART-replete patients does not produce the dramatic effects seen in untreated patients in the 1990s. The mechanism appears to be ART itself: by suppressing viral replication, ART reduces the oxidative stress that drives selenium consumption.

The HIV-selenium story is not a straightforward "selenium fights HIV" narrative. Instead, it is one of selenium status determining how rapidly an untreated HIV infection progresses, mediated by both direct antiviral effects (suppression of viral mutation as discussed above) and indirect effects on T-cell preservation. In the era of universal antiretroviral therapy, the practical relevance is mostly to ensure adequate selenium status as part of nutritional support, not to use high-dose selenium as primary therapy.

Back to Table of Contents

Selenium and Influenza Severity

The Beck-Levander finding that selenium deficiency drives influenza A mutation has been complemented by observational and intervention data on influenza severity and vaccine response.

Beck et al. influenza-mouse model – Selenium-deficient mice infected with mild influenza A developed more severe lung pathology, prolonged viral shedding, and higher mortality than selenium-replete controls. The mechanism involved both impaired host clearance and selection for virulent viral variants as described above.
Broome et al. UK trial 2004 – Twenty-two healthy adults with marginal baseline selenium were randomized to 50, 100, or 200 mcg/day selenium for 15 weeks, then challenged with live attenuated polio vaccine as an immune readout. The 100-mcg/day group showed enhanced T-cell proliferation, increased granzyme expression, and faster viral clearance from stool than the unsupplemented baseline; the 200-mcg/day group did not show additional benefit and the 50-mcg/day group was insufficient.
Vaccine antibody response – Several small trials have documented that selenium supplementation modestly improves seasonal-flu vaccine seroconversion in selenium-marginal elderly subjects, though the effect size is smaller than that of optimizing vitamin D status.
Geographic correlations – Pre-pandemic regional flu mortality data show modest correlations between population-level selenium status and severity of seasonal flu outbreaks, though this is confounded by many other factors.

The practical takeaway is similar to the HIV story: ensuring adequate selenium status is part of immune-system optimization, but supraphysiologic dosing in already-replete adults does not produce additive benefit for flu prevention.

Back to Table of Contents

Sepsis IV Selenium Trials

Severe sepsis and septic shock are associated with rapid depletion of plasma selenium and selenoprotein activity, and selenium IV supplementation has been investigated as adjunct therapy in critical-care medicine for two decades.

Angstwurm et al. 2007 (German Selenium in Intensive Care Trial) – Multicenter trial of 249 ICU patients with severe sepsis randomized to high-dose IV sodium selenite (1000 mcg loading dose followed by 1000 mcg/day for 14 days) vs placebo. Per-protocol analysis showed reduced 28-day mortality (42% vs 56%) in the selenium arm; intention-to-treat analysis was not significant. The trial generated significant enthusiasm for high-dose IV selenium as sepsis adjunctive therapy.
SISPCT trial (Bloos et al. 2016) – Larger and more rigorous 1089-patient trial of high-dose IV selenium (1000 mcg loading then 1000 mcg/day for 14 days) plus or minus procalcitonin-guided antibiotic stewardship. Found no mortality benefit from selenium and a non-significant trend toward harm in some subgroups. The SISPCT result has substantially dampened enthusiasm for high-dose IV selenium in sepsis.
REDOXS trial subgroup – A Canadian trial of glutamine and antioxidants (including 500 mcg/day IV selenium) in ICU patients found increased mortality in the antioxidant arm, leading to early termination. The combination-therapy design makes it hard to isolate the selenium contribution, but the signal added to caution about high-dose IV selenium.
Current critical-care guidance – Major sepsis guidelines (Surviving Sepsis Campaign 2021) do not recommend routine high-dose IV selenium for sepsis. Where selenium IV is used at all, it is usually as part of a "standard ICU micronutrient package" at maintenance doses (60 to 100 mcg/day) rather than as supraphysiologic adjunctive therapy.

Back to Table of Contents

The SELECT Trial Prostate-Cancer Signal

The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was launched in 2001 to confirm the apparent prostate-cancer protection seen in the earlier NPC trial. SELECT randomized 35,533 men aged 50 or older (62 if Black) to one of four arms: selenium alone (200 mcg/day as selenomethionine), vitamin E alone (400 IU/day), both, or neither, with planned 7-year follow-up.

Early termination 2008 – The trial was stopped early when interim analysis showed no benefit from either intervention and a non-significant trend toward harm. Specifically, the vitamin-E-alone arm showed a statistically significant 17% increase in prostate cancer incidence, and the selenium-alone arm showed a non-significant 9% increase. The selenium-plus-vitamin-E arm showed no significant difference, possibly reflecting an interaction.
Extended follow-up findings – Subsequent analyses of the SELECT cohort with longer follow-up showed:
- A statistically significant increase in prostate cancer in the vitamin-E-only arm persisted at 17%.
- In the selenium-only arm, men with the highest baseline plasma selenium (top quartile, >137 ng/mL) showed a 91% increase in high-grade prostate cancer with supplementation — the most worrying single signal from any selenium chemoprevention trial.
- In men with the lowest baseline selenium, supplementation showed no significant benefit either.
Interpretation – The most coherent reading is that selenium supplementation in already-replete adults does not help and may worsen high-grade prostate cancer risk, while the apparent benefit seen in NPC was largely driven by the subset of NPC participants who had low baseline selenium. The NPC and SELECT trials together support a U-shaped dose-response for selenium and prostate cancer: too little and too much both increase risk.
Form vs dose argument – Some commentators have argued that the negative SELECT result reflects the use of pure selenomethionine (which loads non-specifically into the methionine pool) rather than the selenium-enriched yeast used in NPC (which delivers a mix of selenoamino acids including the methylselenocysteine that produces the chemopreventive methylselenol metabolite). Selenium-enriched broccoli or selenium yeast may yet be useful where selenomethionine is not. But this remains hypothesis, not evidence.

The SELECT prostate-cancer signal is the single most important reason that mainstream guidelines do not recommend selenium supplementation for cancer prevention in well-nourished populations. It is also the reason that adults who are not deficient should not take high-dose selenium "for immunity" or any other reason: the safety margin is much narrower than it is for water-soluble vitamins.

Back to Table of Contents

Adult Clinical Applications

Synthesizing all of the above, the practical applications of selenium for immune function in adult patients in developed countries with adequate food supply are concentrated in specific clinical contexts:

Documented deficiency – Plasma selenium below 70 to 80 ng/mL warrants repletion at 100 to 200 mcg/day as selenomethionine or selenized yeast, with recheck at 3 to 6 months. Targets are 120 to 150 ng/mL plasma selenium or 70 to 90 mcg/g SELENOP.
Malabsorption syndromes – Crohn's disease, ulcerative colitis, celiac disease, cystic fibrosis, and short-bowel syndrome routinely produce subclinical selenium deficiency that should be assessed and treated as part of micronutrient management.
Bariatric surgery – Lifelong selenium repletion (100 to 200 mcg/day) is part of standard post-bariatric supplementation, especially after duodenal switch.
Long-term parenteral nutrition – TPN formulations must include selenium (typically 60 to 100 mcg/day IV) to prevent the cardiomyopathy and skeletal myopathy of acquired selenium deficiency.
Hashimoto's thyroiditis with positive anti-TPO – See the Selenium and Thyroid Function page; 200 mcg/day selenomethionine for 6 to 12 months is the typical evidence-based regimen.
Mild Graves' orbitopathy – Selenium 100 mcg twice daily for 6 months per the EUGOGO trial protocol is the strongest guideline-endorsed use of selenium for any indication.
HIV with marginal selenium status not on ART – Increasingly rare in developed-world settings, but still relevant in resource-limited settings; 100 to 200 mcg/day selenomethionine is supported by the Hurwitz Miami trial.
Routine supplementation in selenium-replete adults – Not recommended. The SELECT high-grade prostate cancer signal is sufficient reason not to supplement above 60 to 70 mcg/day in adults with normal baseline selenium status.

Back to Table of Contents

Cautions and the Replete-Patient Problem

Replete-patient SELECT signal – The single most important caution about adult selenium supplementation. In men with high baseline plasma selenium (top SELECT quartile), 200 mcg/day selenomethionine was associated with a 91% increase in high-grade prostate cancer. Do not supplement selenium in adequately nourished adults without a specific clinical indication.
Type 2 diabetes signal from NPC – Long-term follow-up of NPC trial participants showed a small but significant increase in incident type 2 diabetes in the 200 mcg/day selenium arm. The mechanism is incompletely understood but may involve selenoprotein effects on insulin signaling at supraphysiologic intakes.
U-shaped relationship – Cancer, cardiovascular disease, and all-cause mortality data consistently show a U-shaped relationship with selenium status — below ~70 ng/mL plasma and above ~140 to 150 ng/mL plasma both confer increased risk. The narrow "sweet spot" between deficiency and supratherapeutic burden is roughly 90 to 140 ng/mL.
Selenosis – Chronic intake above 400 mcg/day from supplements or accidental dietary overload (Brazil nuts) produces garlic breath, brittle nails, hair loss, peripheral neuropathy, and GI distress. Severe cases require dose reduction or cessation; effects largely reverse over weeks to months.
Tuberculosis – By analogy to vitamin A's mixed signal in pulmonary TB, supraphysiologic selenium in active TB has not been shown beneficial and is not part of standard TB management. Selenium repletion in deficient TB patients is reasonable; supraphysiologic dosing is not.
Drug interactions – May enhance anticoagulant effect; separate from levothyroxine by 4 hours to avoid binding interference; possible interaction with cisplatin-based chemotherapy (selenium may protect tumor cells from chemotherapy-induced oxidative damage and should be discussed with the treating oncologist).
Chronic kidney disease – Impaired SELENOP clearance can produce elevated plasma selenium in advanced CKD; conservative dosing is appropriate.

This content is provided for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting selenium supplementation, particularly if you have a history of prostate cancer, prediabetes, kidney disease, or you eat Brazil nuts regularly.

Back to Table of Contents

Key Research Papers

Beck MA, Kolbeck PC, Rohr LH, et al. (1994). Benign human enterovirus becomes virulent in selenium-deficient mice. Journal of Medical Virology. — DOI: 10.1002/jmv.1890430202
Beck MA, Shi Q, Morris VC, Levander OA (1995). Rapid genomic evolution of a non-virulent Coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. Nature Medicine. — DOI: 10.1038/nm0595-433
Beck MA, Nelson HK, Shi Q, et al. (2001). Selenium deficiency increases the pathology of an influenza virus infection. FASEB Journal. — DOI: 10.1096/fj.00-0721fje
Levander OA, Beck MA (1997). Interacting nutritional and infectious etiologies of Keshan disease: insights from coxsackie virus B-induced myocarditis in mice deficient in selenium or vitamin E. Biological Trace Element Research. — DOI: 10.1007/BF02785233
Baker DH, Smith MC, Foster A, et al. (1997). Increased mortality in HIV-infected adults with low serum selenium. Journal of Acquired Immune Deficiency Syndromes. — DOI: 10.1097/00042560-199707010-00010
Hurwitz BE, Klaus JR, Llabre MM, et al. (2007). Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Archives of Internal Medicine. — DOI: 10.1001/archinte.167.2.148
Broome CS, McArdle F, Kyle JA, et al. (2004). An increase in selenium intake improves immune function and poliovirus handling in adults with marginal selenium status. American Journal of Clinical Nutrition. — DOI: 10.1093/ajcn/80.1.154
Angstwurm MWA, Engelmann L, Zimmermann T, et al. (2007). Selenium in Intensive Care (SIC) study: high-dose selenium reduces 28-day mortality in patients with severe sepsis or septic shock. Critical Care Medicine. — DOI: 10.1097/01.CCM.0000251513.59231.0F
Bloos F, Trips E, Nierhaus A, et al. (2016). Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial (SISPCT). JAMA Internal Medicine. — DOI: 10.1001/jamainternmed.2016.2514
Lippman SM, Klein EA, Goodman PJ, et al. (2009). Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. — DOI: 10.1001/jama.2008.864
Kristal AR, Darke AK, Morris JS, et al. (2014). Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute. — DOI: 10.1093/jnci/djt456
Klein EA, Thompson IM Jr, Tangen CM, et al. (2011). Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. — DOI: 10.1001/jama.2011.1437
Rayman MP (2012). Selenium and human health. The Lancet. — DOI: 10.1016/S0140-6736(11)61452-9
Hoffmann PR, Berry MJ (2008). The influence of selenium on immune responses. Molecular Nutrition & Food Research. — DOI: 10.1002/mnfr.200700330

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents